Tildrakizumab is expected to be indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Schedule A
Indications:
Treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
The requested reimbursement criteria are provided by the applicant and do not
necessarily
reflect
the views of CADTH. Reimbursement criteria from CADTH will be documented in the final
recommendation, if applicable.
Key Milestones2
Call for patient input posted
June 11, 2019
Patient group input closed
July 31, 2019
Clarification:
- Patient input submission received from the Canadian Association of Psoriasis Patients, the Canadian Organization for Rare Disorders, the Canadian Psoriasis Network and the Canadian Skin Patient Alliance
Patient input summary sent for review to patient input groups
September 05, 2019
Patient group comments on input summary closed
September 12, 2019
Clarification:
- Patient input summary feedback received
Submission received
July 15, 2019
Submission accepted
August 26, 2019
Clarification:
- Submission was not accepted for review on 29 Jul 2019
Review initiated
August 27, 2019
Draft CADTH review report(s) sent to sponsor
November 11, 2019
Comments from sponsor on draft CADTH review report(s) received
November 20, 2019
Clarification:
Sponsor waived the opportunity to provide comments
Submission temporarily suspended
Temporary suspension of the review has been lifted
CADTH review team's comments on draft CADTH review report(s) sent to sponsor
January 03, 2020
Canadian Drug Expert Committee (CDEC) meeting
March 17, 2021
CDEC recommendation sent to sponsor and drug plans
May 31, 2021
Embargo period ended
June 14, 2021
CDEC Final Recommendation & CADTH review report(s) issued to sponsor and drug plans
June 21, 2021
CDEC Final Recommendation posted
June 23, 2021
Redaction requests from sponsor on draft CADTH review report(s) received